Mandate

Vinge has advised EQT in connection with the combination with Exeter Property Group

Vinge has advised EQT in connection with the signing of a combination with Exeter Property Group, a global leading real estate investment manager with more than $ 10 billion of assets under management. The total consideration amounts to MUSD 1,870.

Through the transaction, EQT will acquire 100 percent of the Exeter management company and 25 percent of the carried interest in selected existing Exeter funds. Ward Fitzgerald and other Exeter management shareholders will receive their consideration partly in newly issued EQT ordinary shares and partly in cash.

The transaction is subject to customary closing condition and the completion is expected to be carried out at the beginning of the second quarter of 2021.

Vinge’s team mainly consists of Dain Hård Nevonen, Erik Sjöman, Linnéa Sellström, Hampus Olsson and Joel Magnusson, Marcus Glader, Emma Johansson and Johan Wahlbom.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024